(BNTX) BioNTech SE - Ratings and Ratios
Exchange: NASDAQ • Country: Germany • Currency: USD • Type: Common Stock • ISIN: US09075V1026
BNTX: Cancer Vaccines, Immunotherapies, Infectious Disease Treatments
BioNTech SE is a German-based biotechnology company that specializes in developing and commercializing immunotherapies, primarily focusing on mRNA-based treatments for cancer and infectious diseases. The company has gained recognition for its innovative approach to harnessing the immune system to fight various diseases.
BioNTech has a robust pipeline of product candidates, with multiple assets in clinical trials across different types of cancer. Their FixVac platform includes several promising candidates, such as BNT111, which is currently in Phase II clinical trials for advanced melanoma. Additionally, BNT112 is being tested in Phase I/IIa trials for prostate cancer, while BNT113 is in Phase II trials for HPV 16+ head and neck cancers. The company is also exploring BNT114 for triple-negative breast cancer and BNT115 for ovarian cancer, both in Phase I clinical trials.
Beyond these, BioNTech is investigating BNT116 for non-small cell lung cancer and BNT122 for both first-line melanoma and multiple solid tumors. The pipeline further extends to BNT131, BNT141, BNT142, BNT151, BNT152, BNT153, BNT211, and BNT221, all of which are being evaluated for their potential in treating various solid tumors. BNT311 is in Phase II trials for metastatic non-small cell lung cancer and is also being tested in Phase I/II trials for multiple solid tumors. BNT312 is in Phase II trials for multiple solid tumors, and ONC-392 is in Phase III trials for ovarian cancer, with additional Phase I/II trials for multiple solid tumors.
The company is also developing several other candidates, including BNT321, an IgG1 monoclonal antibody in Phase I trials for pancreatic cancer, and BNT411, a small molecule immunomodulator in Phase I trials for solid tumors. BNT322 is in Phase I/Ib trials for multiple solid tumors. Additionally, BioNTech is working on prophylactic vaccines for infectious diseases such as shingles, malaria, tuberculosis, and HSV-2.
BioNTech has established strategic collaborations with key industry players, including Genentech, Sanofi, Genmab, Pfizer, Shanghai Fosun Pharmaceutical, and Ryvu Therapeutics. These partnerships highlight the companys commitment to advancing its pipeline and expanding its reach in the global market.
From a financial perspective, BioNTech has a market capitalization of $28.754 billion USD, with a price-to-book ratio of 1.42 and a price-to-sales ratio of 9.46. While the company currently has a P/E ratio of
Additional Sources for BNTX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BNTX Stock Overview
| Market Cap in USD | 28,728m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2019-10-10 |
BNTX Stock Ratings
| Growth 5y | 49.3% |
| Fundamental | -38.0% |
| Dividend | 1.0% |
| Rel. Strength Industry | 30.3 |
| Analysts | 4.33/5 |
| Fair Price Momentum | 104.56 USD |
| Fair Price DCF | 26.06 USD |
BNTX Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | % |
| Annual Growth 5y | -100.00% |
| Payout Consistency | 1.0% |
BNTX Growth Ratios
| Growth Correlation 3m | 29.8% |
| Growth Correlation 12m | 67.9% |
| Growth Correlation 5y | 0.8% |
| CAGR 5y | 31.72% |
| CAGR/Max DD 5y | 0.39 |
| Sharpe Ratio 12m | 0.68 |
| Alpha | 8.29 |
| Beta | 1.02 |
| Volatility | 52.93% |
| Current Volume | 1364k |
| Average Volume 20d | 735.7k |
As of February 22, 2025, the stock is trading at USD 120.01 with a total of 1,363,954 shares traded.
Over the past week, the price has changed by +0.15%, over one month by +2.35%, over three months by +10.88% and over the past year by +29.40%.
Probably not. Based on ValueRay Fundamental Analyses, BioNTech SE (NASDAQ:BNTX) is currently (February 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -38.01 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BNTX as of February 2025 is 104.56. This means that BNTX is currently overvalued and has a potential downside of -12.87%.
BioNTech SE has received a consensus analysts rating of 4.33. Therefor, it is recommend to buy BNTX.
- Strong Buy: 12
- Buy: 4
- Hold: 5
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, BNTX BioNTech SE will be worth about 125.5 in February 2026. The stock is currently trading at 120.01. This means that the stock has a potential upside of +4.55%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 140.6 | 17.1% |
| Analysts Target Price | 136.6 | 13.8% |
| ValueRay Target Price | 125.5 | 4.5% |